Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: A cohort analysis of the national case register

International Journal of Infectious Diseases

Volumn 39, Issue , 2015, Pages 89-94

  Schnippel, Kathryn ^a   Shearer, Kate ^b   Evans, Denise ^b   Berhanu, Rebecca ^a,b   Dlamini, S'celo ^c   Ndjeka, Norbert ^c  

^a RIGHT TO CARE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL DEPARTMENT OF HEALTH   (South Africa)

Author keywords

Extensively drug resistant tuberculosis; Sub Saharan Africa; TB HIV co infection

Indexed keywords

AMIKACIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAPREOMYCIN; ETHIONAMIDE; KANAMYCIN; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; TERIZIDONE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; COHORT ANALYSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PREDICTION; RETROSPECTIVE STUDY; RIFAMPICIN RESISTANT TUBERCULOSIS; SECONDARY ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT; COMPLICATION; REGISTER; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84943757201     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.09.002     Document Type: Article

References (13)

1. World Health Organization. Global tuberculosis report 2014. Geneva: WHO; 2014. Available at: (accessed 1 June 2015). http://www.who.int/tb/publications/global_report/en/.
2. Directorate of Drug-Resistant TB, TB, and HIV. Multi-drug resistant tuberculosis: a policy framework on decentralised and deinstitutionalised management for South Africa. Pretoria: South African Department of Health; 2011.
3. Directorate of Tuberculosis Control. Management of drug-resistant tuberculosis in South Africa: Policy guidelines. Pretoria: South African Department of Health; 2007.
4. Hanrahan C.F., Dorman S.E., Erasmus L., Koornhof H., Coetzee G.J., Golub J.E. The impact of expanded testing for multidrug resistant tuberculosis using genotype MTBDRplus in South Africa: an observational cohort study. PLoS One 2012, 7(11):e49898. Epub 2012 Nov 30. 10.1371/journal.pone.0049898.
5. South African Department of Health. Clinical guidelines for the management of HIV and AIDS in adults and adolescents. Pretoria: South African Department of Health; 2010. Available at: (accessed 1 June 2015). http://www.sahivsoc.org/upload/documents/Clinical_Guidelines_for_the_Management_of_HIV_AIDS_in_Adults_Adolescents_2010.pdf.
6. Havlir D.V., Kendall M.A., Ive P., Kumwenda J., Swindells S., Qasba S.S., et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
7. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
8. Orenstein E.W., Basu S., Shah N.S., Andrews J.R., Friedland G.H., Moll A.P., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
9. Gupta A., Nadkarni G., Yang W., Chandrasekhar A., Gupte N., Gregory P., et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011, 6(12):e28691. Epub 2011 Dec 29. 10.1371/journal.pone.0028691.
10. Directorate of Drug-Resistant TB, TB, and HIV. Management of drug-resistant tuberculosis: policy guidelines. Pretoria: South African Department of Health; 2011. Available at: (accessed 1 June 2015). http://www.hst.org.za/publications/management-drug-resistant-tuberculosis-policy-guidelines.
11. Loveday M., Wallengren K., Voce A., Margot B., Reddy T. Comparing early treatment outcomes of MDR-TB in a decentralized setting in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012, 16:209-215.
12. Ebonwu J.I., Tint K.S., Ihekweazu C. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberc Lung Dis 2013, 17:1043-1048.
13. Gandhi N.R., Shah N.S., Andrews J.R., Vella V., Moll A.P., Scott M., et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010, 181:80-86.